John Onopchenko,

Chief Executive Officer

OCTOBER 2, 2018

CONFIDENTIAL
1
SAFE HARBOR
Forward-Looking Statements
This presentation includes statements that may be forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. The words “believe,” “estimate,” “expect,” “anticipate,” “project,” “forecast” or the negative thereof and similar expressions,
among others, generally identify forward-looking statements. Forward-looking statements used in this presentation include statements
regarding preliminary financial results f or Q3; revenue, EPS and cash burn guidance for 2018, and 2019; future revenue stabilization and
growth, path to attaining cash independence and becoming cash flow breakeven and EPS positive; new product launches; market opportunity,
market penetration and market share growth; timelines for Ovation, AFX, ChEVAS and Nellix regulatory approvals; development of Next Gen
EVAS; commencement, enrollment, progress and completion of clinical trials; restructuring of debt and compliance with debt covenants;
gathering evidence of product superiority; increased productivity; continuing expense control from efficiencies; and anticipated product
labeling. Endologix® cautions that these forward-looking statements are based on management's current expectations, estimates, forecasts
and projections about Endologix, and assumptions management believes are reasonable, and are subject to risks and uncertainties that may
cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are
not limited to, competition from other products, technologies or therapeutic approaches; changes to laws and regulations applicable to our
company and industry; risks regarding the manufacture of our products; progress of our ongoing clinical trials; clinical trial results; decisions
and the timing of decisions of regulatory authorities regarding our products and potential future products; delays in new product launches;
market acceptance of and reimbursement for our products; our ability to access equity and debt capital on acceptable terms; our ability to
enter into or maintain existing financing arrangements on acceptable terms; and risks relating to foreign currency fluctuations. Additional
information about the factors that may affect Endologix’s operations and results is set forth in Endologix’s annual and periodic reports filed
with the Securities and Exchange Commission. Forward-looking statements contained in this presentation are made only as of the date
hereof, and Endologix undertakes no obligation to release publicly any revisions or updates to forward-looking statements as a result of
subsequent events or developments, except as required by law.

2
Disclosures
Endologix products and associated components are not available in all countries or regions. Please contact your Endologix representative for
details regarding product availability. Prior to use, refer to the “Instructions for Use” for complete and specific indications, contraindications,
all warnings and precautions.

Rx only.

CAUTION: The Nellix® EndoVascular Aneurysm Sealing System is an investigational device. Limited by federal (or United States) law to
investigational use only.

The Nellix® EndoVascular Aneurysm Sealing System is approved in various geographies outside of the United States to treat infrarenal
abdominal aortic aneurysms and is not approved for any other intended use in any geography. CE Mark.

CAUTION: The Ovation Alto™ Abdominal Stent Graft System is an investigational device. Limited by federal (or United States) law to
investigational use only.

LEOPARDTM is a prospective, randomized, multicenter trial with a real-world patient population, some having anatomies outside approved
indications, to provide a head-to-head comparison of EVAR endograft systems.
ENCORE includes results from real-world post market studies. Four percent of patients had vascular characteristics beyond FDA-approved
anatomic IFU. Safety and effectiveness of Ovation when used outside the IFU have not been established.

© 2018 Endologix, Inc. All Rights Reserved.

3
AGENDA
Strategy and Transformation: John Onopchenko
4:15-4:40 p.m.
Five Value Drivers Chief Executive Officer

Vaseem Mahboob
4:40-4:50 p.m. Financial Update Chief Financial Officer

Matt Thompson
4:50-5:00 p.m. Clinical Strategy, Product Portfolio Chief Medical Officer

Marc Schermerhorn, MD
Chief, Division of Vascular and Endovascular Surgery at
5:00-5:10 p.m. Clinical Experience, Ovation Beth Israel Deaconess;
Professor, Surgery, Harvard Medical Center

Michel Reijnen, MD, PhD

5:10-5:20 p.m. Clinical Experience, Nellix Vascular Surgeon, Rijnstate Hospital
Arnhem, Netherlands

5:20-6:00 p.m. Management Q&A

6:00-7:00 p.m. Product Showcase

4
KEY TOPICS WE WILL ADDRESS TODAY
1 Commercial Execution Plan

2 2H 2018 Financial Outlook

3
De-risked Balance Sheet and
Financing Covenants

4 Clinical Trial Updates

5
Product Portfolio Updates and
Leading Clinician Perspectives
5
AAA IS A LEADING CAUSE OF DEATH

Some images may illustrate anatomies outside the approved indications for Endologix products and do not imply safe or effective clinical outcomes
will result from use of such products.
Anatomical challenges can make treatment difficult
6
GLOBAL AORTIC MARKET EXPECTED TO REACH $3.3B BY 2021
Traditional AAA Complex AAA*
$1.6B $1.2B
Current
Market
$2.8B $0.3 $0.8

*Uses not yet $1.3 $0.4

approved for our
products but part 81% endo 31% endo
of our clinical penetrated penetrated
development plan/
in the pipeline Endo Treated Open Opportunity Endo Treated Open Opportunity

Projected $1.4B
Market
$1.9B
$3.3B
9%
(by 2021) 4%
Endo
Endo 86% endo 41% endo
CAGR
CAGR penetrated penetrated

Endologix market model, Third-party market research 7

EVAR IS THE STANDARD OF CARE
But Long-Term Outcomes Need to be Improved

RUPTURE OR REINTERVENTION ANEURYSM-RELATED MORTALITY

EVAR OPEN
n=626 n=626
N% N% Hazard Ratio (95% CI)

All patients 9% 7% 1.24 (0.84-1.83)

66/626 45/626

0-6 months 2% 5% 0.46 (0.24-0.87)

14/626 30/626

>6 months to 2% 1%
rAAA 8 5.4% 4 years 12/599 8/581
1.48 (0.60-3.62)

years EVAR 1.4% >4-8 years 3% 1% 3.46 (1.14-10.52)

OPEN 14/474 4/464

>8 years 5% 1% 5.50 (1.60-18.89)

16/339 3/333

Schermerhorn et al NEJM 2015; 373: 328-338 Patel et al Lancet 2016; 388: 2366
8
THE ENDOLOGIX CALL TO ACTION
Realities We Faced in Q3 2018…
Reality 1: Declining revenues
• Declining U.S. AFX2 sales following recall
• EU sales declines from narrowed Nellix IFU
Reality 2: Unprofitable, cash strapped
• Chased revenue with little regard to profitability
• U.S. sales expense >30% of global revenue
• Lack of effective performance management
• Unrealistic growth required to meet plan
• Covenants did not reflect risk of the business
Reality 3: Execution faltering, credibility eroded
• Broad leadership lapses, planning lacked rigor
• Uncompetitive costs to support platforms globally
• Ineffective incentives drove suboptimal behaviors
…Precipitated Our Strategic Reset
Stabilize revenue, return to growth by Q4 2019
• AFX2 proving durable, strong brand and value prop
• Ovation ENCORE™ data is compelling
• Alto launch preparations underway
Secured cash, lowered cash consumption
• EU 40% reduction in force, 13 fewer countries
• U.S. sales expense reduction ($10M target)
• Cash flow positive projected by 2020
New leadership, focus on program discipline
• Program Management Office, rigorous prioritization
• New leadership in R&D, Manufacturing, Supply
Chain, Quality, Clinical and Regulatory Affairs
• Focus on retention of top performers, bottom 20%
removed
9
THREE STAGES OF TRANSFORMATION
BEGINS WITH FOCUS ON FIVE VALUE DRIVERS
2022 & Beyond

2020-2021 Accelerate Innovation &

Re-establish Durable, Profitable Growth
Predictable Growth
2018-2019 Grow Above Market
Grow Above Market
Strengthen Our Next Gen EVAS Global IDE End
Five Value Drivers

MARKETS Foundation Generate Evidence to Demonstrate Points Met

Superiority of Alto
PRODUCTS Optimize Global Presence & Demonstrate Superiority of Alto2
Restore Credibility Launch Nellix 3.5 in U.S.1
CLINICAL DEV Consistently Achieve Category
Prioritize, Resource, and Initiate Next Gen EVAS Global IDE Leading Compliance
OPEX
Perform Predictably
CULTURE Complete Enrollment in ChEVAS IDE Launch Next Gen EVAS in US & EU
World-Class U.S. & EU Alto
Launch Achieve Cash Flow Breakeven EPS Positive
Next Gen EVAS FIH

PATIENTS FIRST! ACCOUNTABILITY OPERATIONAL EXCELLENCE ONE ENDOLOGIX

Prioritize patients Consistently expect high Ensure compliant, high-quality Aligned actions towards
above all else performance execution achieving results

10
EARLY READ ON Q3 2018
Informed Improved 2018 Guidance U.S. Market Approach
Strengthen Our Foundation: 2018-2019
• Completed planned restructuring in U.S.

• Changes benchmarked by 3rd party experts. Stabilize and Grow AFX2 sales

• Impact of Field Safety Notices (FSN) has been

modest
Grow Ovation, then Alto sales
• Field Team aligned for success, with a lower cost
to serve
Increase Rep Capacity, improve Clinical
• Aortic Account Managers: 72 to 61 Specialist productivity, aligning resources,
and overall lower cost of sales
• Clinical Specialists: 38 to 31

• Continue to closely manage impact of FSNs and Targeted Move Upmarket to higher-
changes on customers and field through Q1 2019 volume centers with Ovation, Alto

Established new structure and performance management process with clearly defined objectives
11
to rep-level Investment in independent customer data, refreshed 2x/yr, completed
U.S. CUSTOMER COVERAGE

27 Accounts per Aortic Account Manager (AAM)

53 Accounts per Clinical Field Specialist (CSF) AAM CSF
12
 U.S. CUSTOMER COVERAGE

Endologix Field Experience

Med-tech EVAR average Endologix
average tenure tenure average tenure

16 7.5 6
YEARS YEARS YEARS
 Top 20 reps consistently generate ~$2.7M per year
 Clinical Specialist average tenure: 4.5 years

27 Accounts per Aortic Account Manager (AAM)

53 Accounts per Clinical Field Specialist (CSF) AAM CSF
13
 2018-2019 TARGET CUSTOMERS
U.S. EVAR CURRENT STATE
Opportunity INNOVATIVE PERFORMANCE VALUE LOCAL
Academic Large Integrated Delivery Corporate Municipal
45,000 procedures at 1,600 hospitals Networks

# HOSPITALS / ANNUAL EVAR 75 / 5,625 125 / 13,125 760 / 21,392 640 / 4,608
% HOSPITALS / % ANNUAL EVAR 5% / 13% 48% / 48% 40% / 10%
8% / 29%

Physicians
AVG # EVAR IMPLANTERS 4.5 5.0 2.5 1.5
AVG EVAR / YR / IMPLANTER 17 21 11 5

TOTAL SALES ~30% ~70%

Endologix
Position AFX2 Mid-single digit Low-double digit
MARKET SHARE to mid-teens

OVATION Low-single digit Mid- to high-single digit

MARKET SHARE

14
Endologix market model, Third-party market research; Annual EVAR for traditional AAA, excludes complex AAA.
GAINING SHARE IN THE U.S. BY YE2019
1 3
Change sales model,
aligning top talent with key
accounts/ opportunities
Shift the basis of
competition from niche
anatomic needs to achieving
superior outcomes
Anticipate AFX2 is stable by YE
2019, Growth then realized by
Ovation, then Alto with both
base and new customer

Target 2% segment shift,

2 4 yielding $10M revenue impact
Deploy clinical specialists to
More effectively leverage support base business Goal is attainable with less than
our clinical evidence (AFX2) 10 additional cases/year/rep

Partnering with High

Volume Customers built Outcomes Not going Evidence more Resulting claims
by Four Common Beliefs: must improve backwards rigorous more clinically
impactful

15
INTERNATIONAL MARKETS: PROGRESS IN ALL MARKETS, FOCUSING
INVESTMENT, ALIGNING TO EXECUTE
EU: Lower Revenue & Lower Investment
 New European device regulations impacting Med- Tech
industry negatively
 Nellix IFU realities drove sequential sales declines. AFX and
Ovation growth remains modest
 Stabilize direct country coverage
 Effective management of expenses as revenue lowered;
retiring distributors in exited countries
 Invest in Alto introduction
 Reinforce Nellix procedural training
Latin America: Continue to invest in existing
distributors to drive growth
 Strong growth in Argentina despite currency issues,
strong market share positions
 Brazil starting to grow again through investments in
channel and market development,
 Expecting product approvals to drive growth
South East Asia: Focus on durable and
predictable growth: Japan and Korea
 Solid growth experience in Japan
 Continue to grow relationship with JLL
 Product launches planned
 Korea: push for reimbursement and product
approval launches in next 12-24 months
 Exit non-profitable, high cost-to-serve markets,
focus on indirect channel
16
 STRATEGIES TO CAPTURE VALUE
AFX2 OVATION / ALTO NELLIX NEXT-GEN EVAS
Unique Pioneered concept of “sac
anatomical ENCORE demonstrates Polymer cuff at
BENEFITS

excellent 5-year data management” proximal aortic

fixation design is
well suited for ENCORE neck with sac
FREEDOM FROM (FF)
Benchmark Statistically significant management
challenging ALL CAUSE MORTALITY 99% mortality benefit vs.
proximal and aspects of Nellix
CONVERSION 99% traditional EVAR despite
distal anatomies. RUPTURE 99%
higher rate of
REINTERVENTION FOR 1
Separate fixation
98%
TYPE IA ENDOLEAK re-intervention from seal and sac
A "door opener” DEVICE-
given ability to RELATED management
REINTERVENTION
93%
serve these
niches.
Low polymer leak rates (0.50-
Prevalence of Type Migration issues
0.75% of patients),
CHALLENGES

IIIB leaks on earlier identified in 2-yr follow-

manageable complication
version of the up led to refined IFU.
product
FSN provides ability to educate Data from pivotal study that is A category defining
Leak rate incidence on older clinicians to recognize a possible leak recruiting in the U.S. product if long term
version of AFX leveling off and mechanisms by which to manage complications of EVAR can
STRATEGIES

Evaluating inclusion of ChEVAS

FSN and LEOPARD report
improved performance of AFXs
since 2015
Data from industry's first
randomized head to head study
will be released at VEITH
polymer leak protocol under the same IDE be addressed and a “game
ALTO to address a broader array of that would address complex changer” if survival
patients given position of sealing anatomies not well served by benefit can be validated
rings existing devices
1 Schermerhorn All-Cause-Mortality analysis of Nellix IDE patients vs. Vascular Quality Initiative® registry
 1. New leadership, new strategy, necessary changes either
implemented or underway
SUMMARY 2. With U.S. restructuring complete, focus on stabilizing AFX2
revenue as a precursor to growth. Alto launch planned in
2019
3. Even with some early success, we remain conservative as we
manage a significant, global reset
4. Our value will be re-built through improved, consistent
execution, reducing our debt dependence, and more rigorous
clinical evidence
5. We have confidence in clearing our financial covenants,
including through the early stages of our strategic reset

18
Vaseem Mahboob,
Chief Financial Officer

OCTOBER 2, 2018

CONFIDENTIAL
19
KEY TOPICS WE WILL ADDRESS TODAY
1 Commercial Execution Plan

2 2H 2018 Financial Outlook

3
De-risked Balance Sheet and
Financing Covenants

4 Clinical Trial Updates

5
Product Portfolio Updates and
Leading Clinician Perspectives
20
Raising Low End of Guidance Range to $150M
Revenue Guidance Bridge
FY 2018 REVENUE
(in millions)
$175 (8)
$150-155M
$167 (7)
$160 (2) (1) - (3)
(2) - (5)
Second-Half Drivers Update
$150 - $155
AFX (3)
MKT (2)
LA (3)
FSN (2)
 Field Safety Notices: impact
Reg (2)
CTS (2) less than anticipated
 U.S. and EU cost to serve:
better than expected in Q3,
monitoring attrition risk
 Executed on OUS
restructuring: assessing
distributor contracts and
timing

Midpoint of Q1 Forecast Pre- Q3 Impact Q4 Markets Q4 FSN Q4 CTS New Guidance

Guidance Reset

21
FY 2018 REVENUE GUIDANCE
(in millions)
FY 2018 REVENUE

$44.7 $34.3 – $150-155M

$42.3
$34.7 $29 - $33 CRITICAL
CONSIDERATIONS
TO CREATE A MORE
COMPETITIVE ENDOLOGIX

 Refocus U.S. sales to

high-volume customers;
lower our cost to serve
and improve productivity
 Exit small, unprofitable
OUS markets
Q1 Actual Q2 Actual Q3 Prelim Q4 Projected
 Effectively convey FSNs
for AFX® and Ovation®
22
 U.S. REVENUE DYNAMICS
Arrows represent sequential growth

Ovation
AFX2

Q317 Q417 Q118 Q218 Q318 Q418 Q119 Q219 Q319 Q419

Strong Ovation
Slow AFX2 Strategic reset Modest growth Stable AFX2 and
growth not
recapture post and associated in Ovation and growing Ovation
enough to
supply issues disruption small declines in
offset AFX2
AFX2
decline

23
 GLOBAL REVENUE DYNAMICS

OUS

U.S.

Q317 Q417 Q118 Q218 Q318 Q418 Q119 Q219 Q319 Q419

Flat & Unstable US Sequentially Profitable &

business + growing US business durable OUS
Unprofitable OUS with lower cost to business
serve

2019 revenue expected to be at least $140M

Formal 2019 guidance to be provided in January
24
OPERATING EXPENSE: PRIORITIZING OUR INVESTMENTS
(in millions)
FY 2019 Operating
Expense at $130-140M
$197
 Delivered synergy benefits post TRIV
R&D merger
$162 $163
CA/RA  Combined 2015 OPEX at $228M
CAPLA $130 - $140
 R&D: Investing in key Next-gen EVAS
EU
 CA/RA: Continue to develop clinical
evidence and fund IDEs
U.S. S&M  S&M: Implemented third-party expert
recommendations on U.S. cost to serve,
designed smaller OUS footprint for
profitability
G&A
 G&A: Continue to drive efficiencies in
2016 2017 2018E 2019E support functions leveraging
technology
25
OPERATING EXPENSE BRIDGE: FY18 to FY19 Target
(in millions)

$160 - $165 (5) 2 (18)

(6.5)
$130 - $140
 R&D: Focus on Next-gen
EVAS, Thoracic program
discontinued
 Clinical: Alto, ChEVAS &
EVAS2 IDE studies
 Sales & Marketing: U.S.
Reps & Clinical ~95. OUS
footprint reduction.
 G&A: Impact of one-time
items in FY18 & reduced
Midpoint of FY18 R&D Clinical investments Cost to Serve G&A FY19 Target
headcount.
Guidance

26
IMPLICATIONS TO FINANCIAL COVENANTS: Status at 3Q 2018

TTM CQ Global TTM CQ

TTM Revenue Actual & Global Liquidity OPEX* Actual &
Covenant CQ+1 Est. Covenant Covenant CQ+1 Est.
Q3FY18 $155 $22.5
Q4FY18 145 22.5 < $165M
Q1FY19 130 22.5 To be
To be Year-end
Q2FY19 130 22.5 updated as
updated as test only
part of
Q3FY19 130 part of 2019 22.5 2019
guidance
Q4FY19 130 22.5 guidance < $140M

Projecting significant cash-burn reduction through 2019

27
* Tested excluding one time items
FINANCING & LIQUIDITY PLANS
ABOVE-MARKET GROWTH &
CASH FLOW BREAKEVEN
2020
STEP 3: Exchange/Refinance $84.5M 2020 maturities in 2019
 Completed exchange of $40.5 of $125M into non-dilutive debt
 Goal: Clear path to cash independence
2019

STEP 2: Right-size business for long-term growth

 Restructure business in line with Med-Tech comparators
 GOAL: Lower cost to serve & reduce 2019 cash burn to <$5M per quarter

2018
STEP 1: Refinance ABL
 Bridge to cash flow positive
 GOAL: Improve short-term liquidity, ABL secured

28
 1. 2H 2018 tracking better than expected
- Updated range reflects disruption risk in U.S. and impact of
market exits
FINANCIAL - Confident in $150M-$155M revenue range for 2018
SUMMARY 2. Q4 guidance $29M-$33M driven by two major factors
- Field Safety Notices for AFX and Ovation
- Commercial changes in U.S. and Europe
3. Management team confident in ability to clear financial covenant risk
- Forecasting $140M floor to 2019 sales

4. Forecasting sequential growth in 2H 2019 with stable U.S. AFX2

business and a growing Ovation business

5. Restructuring actions complete

- Expect Q1 2019 to be in line with new $130M-$140M Operating
Expense run rate

29
Matt Thompson, M.D.,
Chief Medical Officer

OCTOBER 2, 2018

CONFIDENTIAL
30
KEY TOPICS WE WILL ADDRESS TODAY
1 Commercial Execution Plan

2 2H 2018 Financial Outlook

3
De-risked Balance Sheet and
Financing Covenants

4 Clinical Trial Updates

5
Product Portfolio Updates and
Leading Clinician Perspectives
31
CONVENTIONAL EVAR – READY FOR NEW INNOVATION

 Continued outcome limitations of

conventional EVAR
 Public health draft guidelines (NICE)
 Accepted paradigms challenged (failure
modes, surveillance)
 Aneurysm sac enlargement now
established as a dominant failure mode
influencing long-term patient outcomes
(survival)

https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0769

33
THE LIMITATIONS OF CONVENTIONAL EVAR

Open Repair > EVAR

Open repair > EVAR

Open repair > EVAR

Current Device
Competitors

34
ENDOLOGIX PORTFOLIO DIFFERENTIATED FROM
“CONVENTIONAL EVAR”
Anatomically adaptive to mitigate the late
failures compromising “conventional EVAR”
and assessed with unrelenting commitment to
high-quality evidence
Current products achieve excellent outcomes
as assessed by large cohort studies (ENCORE)
and the only randomized controlled trial of
EVAR (LEOPARD™)

We believe that ALTO and EVAS must be

tested for superior outcomes to
“conventional EVAR” and intend to
generate evidence to support this claim

34
STABILIZING AFX2

 Current Type III Endoleak data suggests that the

annual incidence of Strata IIIb is diminishing –
implications for product stabilization

 Continuing to address management of patients with

Strata in collaboration with FDA (FSN and re-lining
instruction)

 LEOPARD study demonstrates that AFX with Duraply®

has equivalent performance to comparable devices
(SCVS 2018)

 Unique anatomical indications and ease of use

35
 AFX TYPE III ENDOLEAKS - CUMULATIVE PREVALENCE
AFX STRATA IIIb
IIIb ENDOLEAKS 0.8
0.7
2.50%
0.6

2.00% 0.5
0.4
Type IIIb Endoleaks Rate

1.50% 0.3
0.2
1.00% 0.1
AFX w/Strata 0
0.50% AFX w/Duraply Y1 Y2 Y3 Y4 Y5 Y6
AFX2 w/Duraply USA STRATA SALES – 18,217
0.00% 7,000
Years Post-Implant
Y1 Y2 Y3 Y4 Y5 6
Y1 Y2 Y3 Y4 Y5 Y6 6,000 64% HAVE
AFX 0.1% 0.4% 0.9% 1.6% 2.0% 2.0% 5,000 REACHED
w/Strata 32/23,965 101/23,965 225/23,960 318/19,606 210/10,598 73/3,614 5Y
AFX 0.2% 0.3% 0.5% 4,000
w/Duraply 30/19,152 40/14,579 22/4,883
3,000
AFX2 w/ 0.1% 0.0%
Duraply 5/5,868 0/285 2,000

1,000

0
2011 2012 2013 2014 2015
36
AFX Strata FIELD SAFETY NOTICE – CLASSIFICATION
 Continuing to address management of patients with Strata in collaboration with
FDA and other regulatory agencies (FSN and re-lining instruction)

 Dec. 2016 – ELGX issued FSN that constituted a voluntary recall of AFX Strata

 2017 - FDA investigated industry-wide incidence of Type III endoleaks

 June 2018 – FDA safety alert to HCPs (Type IIIb Strata)

 July 2018 – ELGX issues FSN reintervention instructions and IIIb rates of all AFX
branded products

 Oct. 2, 2018 – FDA classified our July, 2018 voluntary recall as Class I

 Implications – The typical FDA process involves manufacturers issuing a press

release

 No currently commercially available product impacted. AFX Strata last sold in

2016. All AFX Strata product was removed from global inventory by first half 2017

37
GROWING OVATION, THEN ALTO

 Recent Field Safety Notification (FSN) re-affirming

Instructions For Use (IFU) to support mitigating polymer
leaks

 Root-cause analysis of polymer leaks implicated procedural

aspects, and we are committed to a process of continuous
improvement

 ENCORE publication and sub-analysis in process

 ALTO approval timelines remain on track for 2019

 Intention to generate evidence of superior outcomes

38
INVESTING IN EVIDENCE-DRIVEN PRODUCTS
Q1 2019 Q2 2019 Q3 2019 Q4 2019 2020 2021

EVAS2 enrollment First-in-Human NELLIX 3.5 approval

NG EVAS
predicted to finish Q2/Q3 2019

ChEVAS IDE approval

tracking to Q1/Q2 2019

All cause mortality/etiology –

focus of data presentation
The timelines set forth are currently projected and subject to change based on market conditions, business considerations and other unforeseeable events.
39
NEXT-GENERATION EVAS: NEW PRODUCT DEVELOPMENT

Design goals:

 Translate clinical benefits of Nellix platform to a

wider population

 Aim to eradicate migration as a clinical concern

 Aim to separate aortic fixation, proximal seal, and

aneurysm sac filling

 Multi-generational approach to further expand

applicability and claims

40
ESTABLISHING THE ENDOLOGIX ADVANTAGE

EVAS

Ovation/ALTO/EVAS

Ovation/ALTO/EVAS

AFX2

41
Physician Panel

OCTOBER 2, 2018

CONFIDENTIAL
42
John Onopchenko,
Chief Executive Officer

OCTOBER 2, 2018

CONFIDENTIAL
43
 1. We are a company undertaking a transformation
• With new, highly experienced leaders
• Aligned by a new strategy and a common belief that our products and supporting
clinical evidence are undervalued.
STRENGTHENING
OUR 2. We’ve completed a U.S. and EU restructuring
FOUNDATION • Providing clear line-of-sight to reducing cash burn from $12M to $5M a quarter by
YE ’19
• On a path to cash flow positive by 2020.
• Our return to sequential growth is expected to begin in the 2H 2019.
• Cash management and executing upcoming refinancing remain critically important

3. Our priorities are clear

• Stabilize AFX2 in U.S.
• Build Alto momentum with Ovation
• Focus Nellix in EU with proficient, high-volume, thought-leaders
• Execute EVAS2 and ChEVAS
• Obtain Alto approval 2019
• Advance Next Gen EVAS to design freeze

4. We have confidence in clearing our financial covenants

44
45